Navigation Links
Quest Diagnostics Reports Growth in Revenue and Earnings for Fourth Quarter 2008 and Provides 2009 Guidance
Date:1/26/2009

with further improvements in operating efficiencies."

For the fourth quarter, operating income increased to $317 million, or 17.6% of revenues, from $312 million, or 17.6% of revenues in 2007. The $16 million charge reduced fourth quarter operating income as a percentage of revenues by approximately 1%. Bad debt expense, as a percentage of revenues, improved to 4.3%, compared to 4.4% in 2007. Days sales outstanding improved to 44 days, compared to 45 days at the end of the third quarter of 2008 and 48 days a year ago. Cash from operations increased to $363 million from $355 million in the fourth quarter of 2007. During the quarter, the company repurchased $254 million of its common shares; reduced debt by $45 million; and made capital expenditures of $73 million. Cash and cash equivalents was $254 million at the end of the fourth quarter.

Full Year Performance

Diluted earnings per share increased 14% to $3.23 from $2.84 in 2007. Income from continuing operations increased to $632 million, from $554 million in 2007. Revenues increased 8.1% to $7.2 billion. For the full year, the May 31, 2007 acquisition of AmeriPath increased consolidated revenues by 5.0%.

Operating income for 2008 increased to $1.2 billion, or 16.9% of revenues, compared to $1.1 billion, or 16.3% of revenues in 2007. Cash from operations for 2008 increased to $1.1 billion from $927 million in 2007. During 2008, the company repurchased $254 million of its common shares; reduced debt by $458 million, and made capital expenditures of $213 million.

Outlook for 2009

For 2009, the company expects results from continuing operations as follows: earnings per diluted share of between $3.50 and $3.70, excluding special charges; revenue growth of approximately 3%, and operating income approaching 18% of revenues. Cash from operations is expected to approximate $1 billion, before the expected payment of the $316
'/>"/>

SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Quest Diagnostics Board Authorizes $500 Million in Share Repurchases
2. First Study to Test Real-World Effects of Stun Gun Use Raises Questions about Safety
3. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
4. Xmark Sends Letters to Icagens Board of Directors: Questions Companys Leadership as Well as Motives Behind Adoption of Poison Pill
5. Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results
6. Study of Everest Climbers Questions Oxygen Use
7. Inside out Applesauce Fueling Oklahomas Title Quest
8. U.S. Navy Requested Operations Trial on FDA Hold
9. A simple questionnaire to replace a doctors exam
10. Allsup Outlines 10 Essential Questions People Need to Ask when Evaluating Medicare Plans
11. Hospice Community Encouraged to Respond to Daschle Request to Participate in Information Gathering about Healthcare Concerns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Stress management can be difficult in this day and ... diminish rest and leisure time, stress can mount up and ... a way to manage stress in order to be healthy ... good sense of work-life balance is the key to managing ... of SF Custom Chiropractic. “Stress, left unchecked, can not only ...
(Date:8/1/2014)... 2014 iFitDress.com, a professional company of ... collection of 2014 silver bridesmaid dresses recently. ... to the latest fashion trends. What’s more, they are ... percent off. , iFitDress.com is one of the ... not only silver bridesmaid gowns, but also many other ...
(Date:7/31/2014)... July 31, 2014 Serious buyer, Andrew ... Acid Test concert posters. Owsley Bear Stanley, the King ... the Grateful Dead. According to Hawley, “The Grateful Dead ... acid test parties in San Francisco and Los Angeles ... on three different colors of paper. They were a ...
(Date:7/31/2014)... birth control pills containing high-dose estrogen and a few ... whereas women using some other formulations did not, according ... journal of the American Association for Cancer Research. , ... [birth control pills] in the past year is associated ... or former oral contraceptive use, and that this risk ...
(Date:7/31/2014)... The 2013 PolyU TSI hit a record ... in 2012. The index measures inbound tourists’ satisfaction ... into an overall index. The 2013 index indicates ... Hong Kong over time. , The index shows ... in Hong Kong are attractions (79.27) and transportation ...
Breaking Medicine News(10 mins):Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:iFitDress.com: Beautiful Silver Bridesmaid Dresses at Promotional Prices 2Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3
... the Journal of Hospital Medicine , the risk ... upon general medicine inpatients and those with at least ... factors such as having cancer, chronic diseases such as ... medications, the studies identified other factors which increase the ...
... drugs that target specific molecular mechanisms of cancer have improved ... benefits may come with a cost to the patient,s sex ... the European Society for Medical Oncology (ESMO) in Milan, Italy, ... investigate the impact of cancer therapy on the sexual functioning ...
... Dr. David Nabarro, Assistant Secretary-General at the United Nations and ... Food Security Crisis, will deliver the keynote address at the ... Security on Tuesday, Oct. 19, 5 p.m., at Centre Mont-Royal, ... offer a global perspective on prospects for food and nutrition ...
... HealthDay Reporter , TUESDAY, Oct. 12 (HealthDay News) -- ... just as well as those who receive more, new research ... among U.S. hospitals. The studies are published in the ... Medical Association . In the first study, researchers in ...
... virusrelated virus (XMRV) has been the subject of many ... have created an unclear picture of XMRV,s role in ... November 15 issue of The Journal of Infectious ... possible link between XMRV and prostate cancer but not ...
... a synthetic molecule they designed can block activation of a ... some of those cancer cells to survive chemotherapy. ... cells appear to be protected from the toxic effects of ... protein from protecting the cells, the research suggests. As a ...
Cached Medicine News:Health News:Hospital readmission studies: Influencing factors identified 2Health News:Hospital readmission studies: Influencing factors identified 3Health News:Sexual issues a major concern for cancer patients taking new targeted drugs 2Health News:Coordinator of UN high-level task force to open McGill Food Security Conference 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Blocking an oncogene in liver cancer could be potential therapy option 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 3
(Date:7/31/2014)... MUMBAI , Indien, August 1, 2014 ... ("Cipla") und BioQuiddity Inc. gaben heute bekannt, ... in regionalen Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen ... die das Gebiet der Europäischen Union und ... mit CE-Kennzeichnung versehene und mit Ropivacain gefüllte ...
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today reported financial ... 28, 2014.  , Revenues were $10.6 million in ... in the 2013 second quarter and up sequentially from $10.3 ... first six months of 2014 were $20.9 million, up 15% ... year. , Gross margin for the quarter was 50.0%, ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28
... SEATTLE, WA, Nov. 13 Omeros Corporation (Nasdaq: ... and commercializing products focused on inflammation and disorders of ... hold a conference call on Thursday, November 19, 2009 ... provide a corporate update. Gregory A. Demopulos, M.D., Chairman ...
... EDDA Technology today announced the completion of ... an advanced clinical application designed to enhance efficiency ... planning. , IQQA®-Liver provides a comprehensive toolset ... liver lobes and segments, hepatic lesions, and vascular ...
Cached Medicine Technology:Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19 2EDDA Technology Completes CE Mark for IQQA(R)-Liver for Fast Quantitative Volumetry Assessment from Liver MDCT 2EDDA Technology Completes CE Mark for IQQA(R)-Liver for Fast Quantitative Volumetry Assessment from Liver MDCT 3
Versatrek 528 is versatile as four tests can be performed on one platform such as blood culture, sterile body fluids, mycobacteria and mycobacteria susceptibility testing. This model comes equipped w...
BD Phoenix is an automated microbiology system used for identification and susceptibility testing....
ELP 40- 8 Way Head Strip Plate Washer....
A versatile plate washer and/or dispenser that aspirates from the top down without immersing the aspirating tubes in the well, ensuring overflow protection. 5 programmable protocols....
Medicine Products: